Clinical trials: Systemic Inflammatory Process
Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
The purpose of this trial is to evaluate a CMV vaccine given to related donor/recipient pairs (donors prior to peripheral blood stem cell donation and CMV-seropositive recipients just before and after transplantation) and…
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma
- Trial name
- NCT00285259
- Testing
- VCL-CB01, Phosphate-buffered Saline (PBS)
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Astellas Pharma Inc
Laryngeal Lesions, Systemic Inflammatory Process
Systemic Inflammatory Markers In Vocal Cord Lesions
The aim of this study is to evaluate the levels of systemic inflammatory markers such as PIV, SII, and NPAR in patients with benign and premalignant laryngeal lesions and to determine the diagnostic accuracy of these values using…
- Trial name
- SILVCL (NCT07626125)
- Testing
- Laryngeal polyps, Laryngeal nodules, Laryngeal cysts
- Where
- Turkey (Türkiye)
- Volunteers
- 250 people
- Sponsor
- Antalya Health Sciences University
Sepsis
The Potential of Mesenchymal Stromal Stem Cells to Correct Immune and Metabolic Dysfunctions in Circulating Immune Cells During Sepsis: An Ex Vivo Pilot Study.
Sepsis is a life-threatening organ dysfunction caused by the host's dysregulated immune response to infection. It represents a major global public health challenge.
- Trial name
- REPROCELL (NCT07812012)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Septic Shock
Treatment of Severe Infections With Mesenchymal Stem Cells
The main purpose at the early phase of septic shock on the evolution of organ failure judged by the SOFA (Sepsis Organ Failure Assessment score) score on Day 7 (or the day of death or the day of discharge from the intensive care…
- Trial name
- CHOCMSC (NCT02883803)
- Testing
- Injection of mesenchymal stem cells, Injection of albumin alone
- Where
- 4 sites in France
- Volunteers
- 66 people
- Sponsor
- Central Hospital, Nancy, France
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant…
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias
- Trial name
- HSCT+RIC (NCT01962415)
- Testing
- Hydroxyurea, Alemtuzumab, Fludarabine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Paul Szabolcs
Acute Respiratory Distress Syndrome, Respiratory Failure
MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients
This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS. The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.
- Conditions
- Acute Respiratory Distress Syndrome, Respiratory Failure, Respiratory Distress Syndrome, Respiratory Tract Diseases
- Trial name
- SUMMIT (NCT06308926)
- Testing
- MRG-001 (Low-dose), MRG-001 (High-dose)
- Volunteers
- 60 people
- Sponsor
- MedRegen LLC
Sepsis
Study of Treatment's Echocardiographic Mechanisms
This ancillary study determines whether the Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) [ClinicalTrials.gov Identifier: NCT03434028] treatment arms (restrictive fluids strategy vs.
- Trial name
- NCT03913403
- Testing
- ECHO, Blood Draw
- Where
- 7 sites in United States
- Volunteers
- 210 people
- Sponsor
- Intermountain Health Care, Inc.
Hematologic Malignancy, Leukemia, Acute
Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
This is a prospective, observational cohort study to assess the frequency with which neutropenic patients with hematologic malignancies and hematopoietic cell transplant (HCT) recipients are colonized with…
- Conditions
- Hematologic Malignancy, Leukemia, Acute, Neutropenia, Bloodstream Infection
- Trial name
- SCENE (NCT04710212)
- Testing
- No intervention.
- Where
- 6 sites in United States
- Volunteers
- 168 people
- Sponsor
- Duke University
System Lupus Erythematosus, Systemic Sclerosis (SSc)
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
This study primarily involves the use of BCT301, an anti-CD19 Chemically induced pluripotent stem cell (CiPSC)-derived CAR-iT cells, for the treatment of patients with refractory autoimmune diseases, aiming to evaluate its…
- Conditions
- System Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myositis, Antiphospholipid Syndrome
- Trial name
- NCT07301164
- Testing
- BCT301
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University Third Hospital
Sepsis
Circulating Stem Cells, SDF-1, HIF-1 and Sepsis's Indices in Emergency Abdominal Surgical Patients
Septic shock is a systemic inflammatory response syndrome with acute circulatory failure secondary to a documented infection. It is the most feared complication in ICU patients, with a 50% mortality rate.
- Trial name
- NCT02589535
- Where
- Italy
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University of Foggia
Covid-19, Cytokine Storm
Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia
In this randomized controlled trial (RCT), severe cases of COVID-19 infection will be treated with secretome of hypoxia-mesenchymal stem cells.
- Trial name
- NCT04753476
- Testing
- Injection of Secretome-MSCs, Standard treatment of Covid-19
- Where
- 6 sites in Indonesia
- Volunteers
- 48 people
- Sponsor
- Stem Cell and Cancer Research Indonesia
Septic Shock
Cellular Immunotherapy for Septic Shock: A Phase I Trial
This is a Phase I open label dose escalation trial of human allogeneic bone marrow derived mesenchymal stromal cells (MSCs) for the treatment of septic shock.
- Trial name
- CISS (NCT02421484)
- Testing
- Allogeneic mesenchymal stromal cells
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- Ottawa Hospital Research Institute
Mesenchymal Stromal Cells, Remestemcel-L
MSCs in COVID-19 ARDS
The mortality rate in SARS-CoV-2-related severe ARDS is high despite treatment with antivirals, glucocorticoids, immunoglobulins, and ventilation.
- Conditions
- Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
- Trial name
- NCT04371393
- Testing
- Remestemcel-L
- Where
- 21 sites in United States
- Volunteers
- 223 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Allogeneic Stem Cell Transplantation
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
Bloodstream infections (BSI) caused by bacteria translocating across injured oral mucosa are a significant cause of morbidity and mortality in patients undergoing stem cell transplantation (SCT).
- Trial name
- NCT05579639
- Testing
- Xylitol
- Where
- 3 sites in United States
- Volunteers
- 256 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Sepsis
Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers
Phase I, randomized, parallel group, placebo control, unicentric, interventional study. Thirty two healthy male volunteers aged between 18-35 years will be randomized into the eASCs or placebo group if they meet all the inclusion…
- Trial name
- CELLULA (NCT02328612)
- Testing
- Intravenous infusion of cells
- Where
- Netherlands
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Tigenix S.A.U.
Covid19, Cytokine Release Syndrome
Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan
Beyond supportive care, there are currently no proven treatment options for coronavirus disease (COVID-19) and related pneumonia, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).Investigators have seen…
- Conditions
- Covid19, Cytokine Release Syndrome, Critical Illness, ARDS
- Trial name
- NCT04492501
- Testing
- Therapeutic Plasma exchange, Convalescent Plasma, Tocilizumab
- Where
- Pakistan
- Volunteers
- 600 people
- Sponsor
- UNICEF
Sepsis
Dysfunctions of Human Muscle Stem Cells in Sepsis
Severe critical illness is often complicated by Intensive Care Unit - Acquired Weakness (ICU-AW), which is associated with increased in and post-ICU mortality, with delayed weaning from mechanical ventilation and with long-term…
- Trial name
- DISCUSS (NCT02789995)
- Testing
- Human biological samples
- Where
- 7 sites in France
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
EBV Viremia, CMV Viremia
25BT056: Basket Study of Viral Cytotoxic T Lymphocytes
This study is evaluating the safety and effectiveness of virus-specific cytotoxic T lymphocytes (vCTLs) for treating difficult-to-control viral infections caused by cytomegalovirus (CMV), adenovirus (ADV), Epstein-Barr virus…
- Conditions
- EBV Viremia, CMV Viremia, BK Viremia, Adenovirus
- Trial name
- NCT07873970
- Testing
- Virus-Specific Cytotoxic T Lymphocytes (vCTLs)
- Volunteers
- 35 people
- Sponsor
- Children's Hospital of Philadelphia
Sepsis, Septic Shock
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
Sepsis remains the leading cause of ICU admission in neutropenic patients. This condition remains associated with a high morbidity and mortality, with hospital mortality of 60% when vasopressors are required.
- Conditions
- Sepsis, Septic Shock, Hematologic Malignancy, Tumor
- Trial name
- NCT05443854
- Testing
- Aminoglycosides intervention, Lack of protective isolation intervention, No systematic aminoglycosides intervention - standard arm
- Volunteers
- 340 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Intraventricular Hemorrhage, Sepsis
Protective Effects of Delayed Cord Clamping in Very Low Birth Weight (VLBW) Infants
The purpose of this study is to determine whether the intervention of delaying cord clamping for 30 to 45 seconds followed by one milking of the cord while simultaneously lowering the VLBW infants below the introitus will result…
- Trial name
- NCT00818220
- Testing
- delayed umbilical cord clamping, Immediate cord clamping
- Where
- United States
- Volunteers
- 211 people
- Sponsor
- University of Rhode Island